Editor's Highlights—January 2025

Immune-mediated inflammatory skin diseases (IMIDs) frequently result in chronic and debilitating health conditions that significantly diminish patients' quality of life. In the past 10 years, we have seen a huge breakthrough in treating IMIDs by blocking cytokines or cytokine receptors through monoclonal antibodies and by blocking the signaling pathway using Janus kinase (JAK) inhibitors. Nowadays, an increasing number of patients with different immune-mediated skin diseases are being treated with systemic and topical JAK inhibitors. Dermatologists frequently use these new medications in an off-label way to treat various skin diseases. Thus, in the January issue of the Journal, we show the efficacy of JAK inhibitors in treating erythema nodosum leprosum, silicone-induced foreign body reactions in a patient with chronic graft-versus-host disease, but also cover the potential side effects of JAK inhibitors in treating skin diseases.